Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L I Gordon

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Archives of Dermatology|August 1, 1986
Evaluation of computed tomography and radionuclide scanning in the staging of cutaneous T-cell lymphomaS T Rosen, R Gore, J Brennan, et al.
Bone Marrow Transplantation|August 3, 2005
Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSFM Tomblyn, L I Gordon, S Singhal, et al.
Bone Marrow Transplantation|December 3, 2003
Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?J Cilley, C Rihn, J Monreal, et al.
Cellular Immunology|February 1, 1992
Inhibition of NK cell-mediated cytotoxicity by oxysterolsO Kucuk, J Stoner-Picking, S Yachnin, et al.
Bone Marrow Transplantation|November 20, 2002
Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 10(9)/l neutrophils on 3 consecutive days to define myeloid recoveryM Y Ali, Y Oyama, J Monreal, et al.
American Journal of Clinical Oncology|December 1, 1991
Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot studyA S Spiers, J H Weens, J M Rowe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphomaM Hoffman, M S Tallman, D Hakimian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology GroupH S Hochster, M M Oken, J N Winter, et al.
The New England Journal of Medicine|November 5, 1992
Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphomaL I Gordon, D Harrington, J Andersen, et al.
Leukemia & Lymphoma|November 1, 1993
Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomasT M Kuzel, S T Rosen, L I Gordon, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Archives of Dermatology|August 1, 1986
Evaluation of computed tomography and radionuclide scanning in the staging of cutaneous T-cell lymphomaS T Rosen, R Gore, J Brennan, et al.
Bone Marrow Transplantation|August 3, 2005
Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSFM Tomblyn, L I Gordon, S Singhal, et al.
Bone Marrow Transplantation|December 3, 2003
Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?J Cilley, C Rihn, J Monreal, et al.
Cellular Immunology|February 1, 1992
Inhibition of NK cell-mediated cytotoxicity by oxysterolsO Kucuk, J Stoner-Picking, S Yachnin, et al.
Bone Marrow Transplantation|November 20, 2002
Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 10(9)/l neutrophils on 3 consecutive days to define myeloid recoveryM Y Ali, Y Oyama, J Monreal, et al.
American Journal of Clinical Oncology|December 1, 1991
Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot studyA S Spiers, J H Weens, J M Rowe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphomaM Hoffman, M S Tallman, D Hakimian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology GroupH S Hochster, M M Oken, J N Winter, et al.
The New England Journal of Medicine|November 5, 1992
Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphomaL I Gordon, D Harrington, J Andersen, et al.
Leukemia & Lymphoma|November 1, 1993
Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomasT M Kuzel, S T Rosen, L I Gordon, et al.
Pageof 8